Russell H. Wiesner

Russell H. Wiesner's AcademicInfluence.com Rankings

Russell H. Wiesner

Philosophy

#4108

World Rank

#6501

Historical Rank

Logic

#1642

World Rank

#2444

Historical Rank

philosophy Degrees

Russell H. Wiesner

Mathematics

#5058

World Rank

#7154

Historical Rank

Statistics

#307

World Rank

#369

Historical Rank

mathematics Degrees

Download Badge

Philosophy
Mathematics

Russell H. Wiesner's Degrees

PhD Biostatistics University of California, Berkeley
Doctorate Medicine University of California, San Francisco

Why Is Russell H. Wiesner Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Russell H. Wiesner's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A model to predict survival in patients with end‐stage liver disease (2001) (2667)
Model for end-stage liver disease (MELD) and allocation of donor livers. (2003) (2252)
A model to predict survival in patients with end-stage liver disease. (2001) (1889)
Banff schema for grading liver allograft rejection: An international consensus document (1997) (1152)
Hyponatremia and mortality among patients on the liver-transplant waiting list. (2008) (944)
MELD and PELD: Application of survival models to liver allocation (2001) (826)
The new liver allocation system: Moving toward evidence‐based transplantation policy (2002) (654)
Evidence-based incorporation of serum sodium concentration into MELD. (2006) (638)
Primary sclerosing cholangitis: Natural history, prognostic factors and survival analysis (1989) (588)
Predictors of patient and graft survival following liver transplantation for hepatitis C (1998) (570)
Pulmonary hemodynamics and perioperative cardiopulmonary‐related mortality in patients with portopulmonary hypertension undergoing liver transplantation (2000) (513)
Epstein-barr virus-induced posttransplant lymphoproliferative disorders (1999) (475)
MELD accurately predicts mortality in patients with alcoholic hepatitis (2005) (463)
Acute hepatic allograft rejection: Incidence, risk factors, and impact on outcome (1998) (456)
Update of the International Banff Schema for liver allograft rejection: Working recommendations for the histopathologic staging and reporting of chronic rejection (2000) (452)
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. (1994) (438)
Report of the First International Liver Transplantation Society Expert Panel Consensus Conference on Liver Transplantation and Hepatitis C (2003) (426)
Results of the first year of the new liver allocation plan (2004) (425)
Natural history of hepatopulmonary syndrome: Impact of liver transplantation (2005) (415)
Ischemic‐type biliary complications after orthotopic liver transplantation (1992) (415)
Clinicopathologic features of the syndrome of primary sclerosing cholangitis (1980) (389)
Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. (1997) (381)
Pretransplantation assessment of the risk of lymphoproliferative disorder. (1995) (377)
A revised natural history model for primary sclerosing cholangitis. (1997) (349)
Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. (1991) (334)
Portopulmonary hypertension: Results from a 10‐year screening algorithm (2006) (316)
Primary sclerosing cholangitis: findings on cholangiography and pancreatography. (1983) (301)
Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis (1991) (299)
Long‐term results of patients undergoing liver transplantation for primary sclerosing cholangitis (1999) (297)
Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. (1998) (297)
Recurrence of primary sclerosing cholangitis following liver transplantation (1999) (296)
Use of fatty donor liver is associated with diminished early patient and graft survival. (1996) (295)
Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis (1981) (290)
TT‐virus infection in north american blood donors, patients with fulminant hepatic failure, and cryptogenic cirrhosis (1998) (289)
Whipple's disease: clinical, biochemical, and histopathologic features and assessment of treatment in 29 patients. (1988) (276)
Survival in Portopulmonary Hypertension: Mayo Clinic Experience Categorized by Treatment Subgroups (2008) (275)
Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. (2004) (271)
Current concepts in primary sclerosing cholangitis. (1984) (264)
Risk Factors for and Clinical Course of Non‐Anastomotic Biliary Strictures After Liver Transplantation (2003) (260)
A randomized double‐blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients (2001) (256)
Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension (1999) (255)
Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease (2001) (250)
Primary sclerosing cholangitis: refinement and validation of survival models. (1992) (248)
Evolving Frequency and Outcomes of Liver Transplantation Based on Etiology of Liver Disease (2013) (248)
Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. (2000) (247)
Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. (1995) (246)
Improving liver allocation: MELD and PELD (2004) (245)
Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients. (1996) (245)
Liver transplantation for hepatocellular carcinoma: The MELD impact (2004) (245)
Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C (2002) (241)
Incidence, distribution, and outcome of episodes of infection in 100 orthotopic liver transplantations. (1989) (236)
Hepatopulmonary syndrome: a prospective study of relationships between severity of liver disease, PaO(2) response to 100% oxygen, and brain uptake after (99m)Tc MAA lung scanning. (2000) (231)
Efficacy of liver transplantation in patients with primary biliary cirrhosis. (1989) (221)
A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. (1998) (214)
Diagnosis and Monitoring of Whipple Disease by Polymerase Chain Reaction (1997) (214)
Combined Liver Transplantation and Gastric Sleeve Resection for Patients With Medically Complicated Obesity and End‐Stage Liver Disease (2013) (214)
Intrapulmonary vascular dilatations (IPVD) in liver transplant candidates. Screening by two-dimensional contrast-enhanced echocardiography. (1990) (214)
MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients (2004) (212)
Hepatopulmonary syndrome with progressive hypoxemia as an indication for liver transplantation: case reports and literature review. (1997) (209)
Diagnostic features and clinical outcome of ischemic‐type biliary complications after liver transplantation (1993) (204)
Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation (2000) (199)
Weight change and obesity after liver transplantation: incidence and risk factors. (1998) (198)
A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. (1990) (195)
Quality of life before and after liver transplantation for cholestatic liver disease (1999) (193)
Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. (1996) (192)
Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation (1998) (189)
Bone disease in liver transplant recipients: incidence, timing, and risk factors. (1991) (187)
Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. (1993) (184)
Accuracy of doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates (2000) (183)
Comparison of the clinicopathologic features of primary sclerosing cholangitis and primary biliary cirrhosis. (1985) (183)
Cyclosporine-induced hypertension after transplantation. (1994) (182)
Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival. (1989) (182)
The acute vanishing bile duct syndrome (acute irreversible rejection) after orthotopic liver transplantation (1987) (181)
Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. (1997) (181)
Hepatobiliary carcinoma associated with primary sclerosing cholangitis and chronic ulcerative colitis. (1985) (180)
Recurrent autoimmune hepatitis after orthotopic liver transplantation (2001) (179)
Gallbladder disease in patients with primary sclerosing cholangitis. (1988) (173)
Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus (FK506). (1997) (172)
Increased Bile Duct Complications in Liver Transplantation Across the ABO Barrier (1993) (171)
Differential Effects of Donor Age in Liver Transplant Recipients Infected With Hepatitis B, Hepatitis C and Without Viral Hepatitis (2005) (171)
MELD and Other Factors Associated with Survival after Liver Transplantation (2004) (170)
Prognostic features and role of liver transplantation in severe corticosteroid‐treated autoimmune chronic active hepatitis (1992) (170)
Resource utilization in liver transplantation: effects of patient characteristics and clinical practice. NIDDK Liver Transplantation Database Group. (1999) (168)
Summary report of a national conference: Evolving concepts in liver allocation in the MELD and PELD era (2004) (164)
Assessment of nutritional status of patients with end-stage liver disease undergoing liver transplantation. (1989) (159)
Recurrence of nonalcoholic steatohepatitis following liver transplantation. (1996) (157)
Prospective trial of penicillamine in primary sclerosing cholangitis. (1988) (154)
Trial of penicillamine in advanced primary biliary cirrhosis. (1985) (154)
Long‐term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation (2007) (153)
Clinicopathologic features of the syndrome of primary sclerosing cholangitis. (1980) (152)
Idiopathic adulthood ductopenia. A cause of chronic cholestatic liver disease and biliary cirrhosis. (1988) (151)
Cytomegalovirus hepatitis in liver transplantation: prospective analysis of 93 consecutive orthotopic liver transplantations. (1989) (150)
Chronic renal dysfunction late after liver transplantation (2002) (148)
SYSTEMIC AND RENAL HEMODYNAMIC DIFFERENCES BETWEEN FK506 AND CYCLOSPORINE IN LIVER TRANSPLANT RECIPIENTS (1993) (147)
Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis. (1993) (146)
FK506‐induced neurotoxicity in liver transplantation (1994) (145)
Selection and timing of liver transplantation in primary biliary cirrhosis and primary sclerosing cholangitis (1992) (142)
Age and liver transplantation: a report of the Liver Transplantation Database. (1998) (142)
Current concepts in cell‐mediated hepatic allograft rejection leading to ductopenia and liver failure (1991) (142)
Post‐Transplant Lymphoproliferative Disorders Following Liver Transplantation: Incidence, Risk Factors and Survival (2006) (141)
Neurotoxicity in liver transplant recipients with cyclosporine immunosuppression (1995) (141)
SELECTIVE BOWEL DECONTAMINATION TO DECREASE GRAM‐NEGATIVE AEROBIC BACTERIAL AND CANDIDA COLONIZATION AND PREVENT INFECTION AFTER ORTHOTOPIC LIVER TRANSPLANTATION (1988) (140)
Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis. (1989) (136)
A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. (1996) (133)
Peristomal varices after proctocolectomy in patients with primary sclerosing cholangitis. (1986) (132)
Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. (2002) (132)
Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation (2009) (130)
OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation. (1995) (129)
Floxuridine‐induced sclerosing cholangitis: An ischemic cholangiopathy? (1989) (129)
Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease. (1990) (125)
The relative role of the child‐pugh classification and the mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis (1999) (125)
Mycophenolate mofetil combination therapy improves long‐term outcomes after liver transplantation in patients with and without hepatitis C (2005) (125)
Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: Lessons on tolerability and efficacy (2002) (124)
A Pilot Study of the Safety and Tolerability of Etanercept in Patients with Alcoholic Hepatitis (2004) (123)
Diminished survival in asymptomatic primary biliary cirrhosis. A prospective study. (1990) (123)
Hepatopulmonary syndrome: Favorable outcomes in the MELD exception era (2013) (123)
Seroconversion to human herpesvirus 6 following liver transplantation is a marker of cytomegalovirus disease. (1997) (123)
Preoperative hepatic artery chemoembolization followed by orthotopic liver transplantation for hepatocellular carcinoma. (1999) (123)
The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. (1991) (121)
The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. (1997) (121)
Insulin Resistance, Serum Adipokines and Risk of Fibrosis Progression in Patients Transplanted for Hepatitis C (2009) (120)
Hilar biliary strictures after liver transplantation: cholangiography and percutaneous treatment. (1990) (119)
Recurrence of primary biliary cirrhosis after liver transplantation: Histologic estimate of incidence and natural history (2003) (119)
The first 100 liver transplantations at the Mayo Clinic. (1989) (118)
Immunohistochemical characterization of hepatic lymphocytes in primary biliary cirrhosis in comparison with primary sclerosing cholangitis and autoimmune chronic active hepatitis. (1993) (116)
Increased risk of chronic liver failure in adults with heterozygous α‐antitrypsin deficiency (1998) (115)
Predicting Survival among Patients Listed for Liver Transplantation: An Assessment of Serial MELD Measurements (2004) (111)
Cytomegalovirus and its association with hepatic artery thrombosis after liver transplantation. (1998) (110)
Primary Sclerosing Cholangitis (1984) (110)
Manifestations of nonsuppurative cholangitis in chronic hepatobiliary diseases: morphologic spectrum, clinical correlations and terminology. (2008) (110)
Recurrent and new hepatitis C virus infection after liver transplantation (1999) (109)
Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension. (2011) (109)
Elevation of plasma endothelin associated with systemic hypertension in humans following orthotopic liver transplantation. (1991) (106)
Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States (2017) (106)
Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation. (1994) (105)
Increased waiting time for liver transplantation results in higher mortality. (1997) (104)
Diagnosis of chronic hepatitis C after liver transplantation by the detection of viral sequences with polymerase chain reaction (1992) (103)
Histological evidence for recurrence of primary biliary cirrhosis after liver transplantation (1993) (103)
Primary sclerosing cholangitis and celiac disease. A novel association. (1988) (102)
The metabolic bone disease of primary sclerosing cholangitis (1991) (102)
Immunohistochemical evidence of disease recurrence after liver transplantation for primary biliary cirrhosis. (1996) (101)
INFLUENCE OF POSITIVE LYMPHOCYTE CROSSMATCH AND HLA MISMATCHING ON VANISHING BILE DUCT SYNDROME IN HUMAN LIVER ALLOGRAFTS (1988) (100)
The Budd-Chiari syndrome. Medical and surgical management of 30 patients. (1985) (99)
Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. (2003) (98)
Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer? (1997) (97)
A prognostic model for the outcome of liver transplantation in patients with cholestatic liver disease (1997) (97)
Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection (1994) (96)
Double‐dose accelerated hepatitis B vaccine in patients with end‐stage liver disease (2001) (96)
The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study. (1995) (94)
Azathioprine hepatotoxicity after liver transplantation (1991) (94)
Evolving concepts in the diagnosis, pathogenesis, and treatment of chronic hepatic allograft rejection. (1999) (94)
Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation (1997) (93)
Pulmonary contraindications, indications and MELD exceptions for liver transplantation: a contemporary view and look forward. (2013) (93)
Nonoperative dilatation of dominant strictures in primary sclerosing cholangitis. (1985) (92)
Long‐term results and modeling to predict outcomes in recipients with HCV infection: Results of the NIDDK liver transplantation database (2004) (92)
Complications of liver biopsy in liver transplant patients: Increased sepsis associated with choledochojejunostomy (1991) (92)
Cholangiocarcinoma complicating primary sclerosing cholangitis: cholangiographic appearances. (1985) (91)
Safety and efficacy of hepatitis A vaccination in liver transplantation recipients. (2001) (90)
Natural history of vancomycin‐resistant enterococcal colonization in liver and kidney transplant recipients (2001) (89)
Optimal timing of liver transplantation for primary biliary cirrhosis (1998) (89)
Present state of immunosuppressive therapy in liver transplant recipients (2011) (89)
Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database. (1997) (88)
SPLENIC ARTERY ANEURYSMS IN LIVER TRANSPLANT PATIENTS (1988) (88)
Improving Outcomes of Liver Retransplantation: An Analysis of Trends and the Impact of Hepatitis C Infection (2008) (85)
Primary sclerosing cholangitis with normal serum alkaline phosphatase activity. (1988) (85)
Long‐term outcome of human leukocyte antigen mismatching in liver transplantation: Results of the national institute of diabetes and digestive and kidney diseases liver transplantation database (2008) (84)
Human herpesvirus 6 seronegativity before transplantation predicts the occurrence of fungal infection in liver transplant recipients. (1999) (84)
Liver and intestine transplantation (2003) (84)
Nonalcoholic Steatohepatitis is the Most Rapidly Growing Indication for Simultaneous Liver Kidney Transplantation in the United States (2016) (83)
A prospective comparison of molecular diagnostic techniques for the early detection of cytomegalovirus in liver transplant recipients. (1995) (82)
Late hypertension after liver transplantation: a comparison of cyclosporine and tacrolimus (FK 506). (1998) (81)
EFFICACY OF GANCICLOVIR IN LIVER AND KIDNEY TRANSPLANT RECIPIENTS WITH SEVERE CYTOMEGALOVIRUS INFECTION (1988) (81)
Recent advances in liver transplantation. (2003) (81)
Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation (1999) (79)
Use of sirolimus in liver transplant recipients with renal insufficiency: A systematic review and meta‐analysis (2010) (79)
Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation: a report of the U.S. Multicenter Liver Study Group. (1997) (78)
Serum type III procollagen peptide concentrations in severe chronic active hepatitis: Relationship to cirrhosis and disease activity (1987) (78)
Prevention of Post‐transplant Cardiovascular Disease – Report and Recommendations of an Ad Hoc Group 1 (2002) (77)
Intrahepatic cholangiectases and large‐duct obliteration in primary sclerosing cholangitis (1986) (77)
Causes and outcome of seizures in liver transplant recipients (1996) (77)
Abnormalities in tests of copper metabolism in primary sclerosing cholangitis. (1985) (77)
Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy. (1986) (76)
The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. (2002) (75)
Model for end‐stage liver disease (MELD) exception guidelines (2006) (75)
Hepatic allograft rejection: new developments in terminology, diagnosis, prevention, and treatment. (1993) (75)
The economic impact of cytomegalovirus infection after liver transplantation. (2000) (74)
De Novo Sirolimus and Reduced‐Dose Tacrolimus Versus Standard‐Dose Tacrolimus After Liver Transplantation: The 2000–2003 Phase II Prospective Randomized Trial (2014) (74)
Primary sclerosing cholangitis: value of cholangiography in determining the prognosis. (1991) (73)
Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis. (1995) (73)
Recurrent Primary Biliary Cirrhosis After Liver Transplantation (2010) (73)
Analysis of factors that predict alcohol relapse following liver transplantation (2004) (72)
Clinical and radiologic features of cerebral edema in fulminant hepatic failure. (1995) (72)
Increased risk of chronic liver failure in adults with heterozygous alpha1-antitrypsin deficiency. (1998) (72)
Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. (1996) (72)
Liver transplantation for end-stage alcoholic liver disease: an assessment of outcomes. (1997) (72)
Hepatic retransplantation in cholestatic liver disease: Impact of the interval to retransplantation on survival and resource utilization (1999) (71)
Transplant Center Quality Assessment Using a Continuously Updatable, Risk‐Adjusted Technique (CUSUM) (2006) (71)
Severe ductopenic rejection following liver transplantation: incidence, time of onset, risk factors, treatment, and outcome. (1992) (71)
Increased risk of hepatocellular carcinoma in patients infected with hepatitis C genotype 1b. (1996) (70)
Comparative allograft histology after liver transplantation for cryptogenic cirrhosis, alcohol, hepatitis C, and cholestatic liver diseases. (2000) (70)
Patient selection in an era of donor liver shortage: current US policy (2005) (70)
Detection of cytomegalovirus DNA in sera of liver transplant recipients (1994) (68)
Pouchitis disease course after orthotopic liver transplantation in patients with primary sclerosing cholangitis and an ileal pouch-anal anastomosis. (1995) (67)
Acute liver failure: results of a 5-year clinical protocol. (1995) (67)
Liver transplantation for cryptogenic cirrhosis. (1997) (66)
Organ-specific patterns of donor antigen-specific hyporeactivity and peripheral blood allogeneic microchimerism in lung, kidney, and liver transplant recipients. (1995) (66)
Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced posttransplant lymphoproliferative disorder. (1996) (66)
Renal hemodynamics, urinary eicosanoids, and endothelin after liver transplantation. (1992) (65)
Comparison of surgical treatment of ulcerative colitis associated with primary sclerosing cholangitis: ileal pouch-anal anastomosis versus Brooke ileostomy. (1996) (64)
Evolving Frequency and Outcomes of Simultaneous Liver Kidney Transplants Based on Liver Disease Etiology (2014) (64)
Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation: a prospective derivation and validation cohort analysis. (1998) (62)
Embolization of portosystemic shunts for treatment of medically refractory hepatic encephalopathy (2016) (62)
Clinical significance of viral load in the diagnosis of cytomegalovirus disease after liver transplantation. (1998) (62)
HEMOSTATIC EVALUATION OF PATIENTS UNDERGOING LIVER TRANSPLANTATION (1987) (62)
Analysis of the reversibility of chronic liver allograft rejection implications for a staging schema. (1999) (62)
Long-term comparison of tacrolimus versus cyclosporine in liver transplantation (1998) (61)
Liver transplantation for primary sclerosing cholangitis: timing, outcome, impact of inflammatory bowel disease and recurrence of disease. (2001) (61)
Current concepts. Primary sclerosing cholangitis. (1994) (61)
Lack of association between cytomegalovirus infection, HLA matching and the vanishing bile duct syndrome after liver transplantation (1992) (60)
Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin. (1993) (60)
Nutritional support for liver transplantation: identifying caloric and protein requirements. (1994) (60)
Cholangiocarcinoma complicating primary sclerosing cholangitis. (1991) (59)
Resource Utilization in Liver Transplantation: Effects of Patient Characteristics and Clinical Practice (2000) (59)
Complications and risk factors after ileal pouch-anal anastomosis for ulcerative colitis associated with primary sclerosing cholangitis. (1993) (58)
Orthotopic liver transplantation for hereditary fibrinogen amyloidosis. (2003) (57)
The impact of immunosuppressive regimens on the cost of liver transplantation--results from the U.S. FK506 multicenter trial. (1995) (57)
Enhanced autoreactivity of T‐lymphocytes in primary sclerosing cholangitis (1987) (57)
Clinical and statistical analyses of new and evolving therapies for primary biliary cirrhosis (1988) (56)
Treatment of recurrent hepatocellular carcinoma after liver transplantation (2011) (55)
Outcome of liver transplantation for familial amyloidotic polyneuropathy (2003) (55)
Relevance and risk factors of enterococcal bacteremia following liver transplantation. (1996) (54)
Early Detection of Hepatitis C Allograft Reinfection after Orthotopic Liver Transplantation: A Molecular and Histologic Study (2000) (54)
Anti‐tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients (2012) (53)
Incidence of cytomegalovirus infection and its relationship to donor-recipient serologic status in liver transplantation. (1987) (53)
Differential allograft gene expression in acute cellular rejection and recurrence of hepatitis C after liver transplantation (2002) (52)
Outcomes of Liver Transplantation Alone After Listing for Simultaneous Kidney: Comparison to Simultaneous Liver Kidney Transplantation (2015) (52)
The syndrome of primary sclerosing cholangitis. (1990) (52)
Renal sodium handling with cyclosporin A and FK506 after orthotopic liver transplantation. (1995) (52)
Bone loss after orthotopic liver transplantation: FK 506 versus cyclosporine. (1996) (51)
Early diagnosis of cytomegalovirus hepatitis in liver transplant recipients: Role of immunostaining, dna hybridization and culture of hepatic tissue (1990) (50)
Pirfenidone in the Treatment of Primary Sclerosing Cholangitis (2004) (50)
Carolina rinse solution decreases liver injury during clinical liver transplantation. (1993) (49)
Diagnosis and treatment of primary sclerosing cholangitis. (1985) (49)
Celiac disease autoantibodies in severe autoimmune liver disease and the effect of liver transplantation (2008) (49)
Adaptation of the mayo primary biliary cirrhosis natural history model for application in liver transplant candidates (2000) (49)
Advances in the diagnosis, treatment, and prevention of cytomegalovirus infections after liver transplantation. (1993) (48)
Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group. (1993) (48)
MELD / PELD and the allocation of deceased donor livers for status 1 recipients with acute fulminant hepatic failure, primary nonfunction, hepatic artery thrombosis, and acute Wilson's disease (2004) (48)
Intracerebral hemorrhage in liver transplant recipients. (1995) (48)
Reduced Priority MELD Score for Hepatocellular Carcinoma Does Not Adversely Impact Candidate Survival Awaiting Liver Transplantation (2006) (47)
Cyclosporin A-induced reversible cortical blindness. (1988) (46)
Noninvasive diagnosis of acute cellular rejection in liver transplant recipients: A proteomic signature validated by enzyme‐linked immunosorbent assay (2011) (46)
Loss of nocturnal blood pressure fall after liver transplantation during immunosuppressive therapy. (1995) (46)
Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: predicting outcomes with natural history models. (1998) (46)
Phaeohyphomycosis due to Scopulariopsis brumptii in a liver transplant recipient. (1994) (45)
Neuromuscular complications associated with liver transplantation (1996) (44)
CD40L (CD154) expression in human liver allografts during chronic ductopenic rejection. (1999) (44)
Evidence‐based evolution of the MELD/PELD liver allocation policy (2005) (44)
Non-A, non-B fulminant hepatitis is also non-E and non-C. (1994) (43)
Clinical outcome of ischemic-type biliary complications after liver transplantation. (1993) (43)
Hemodynamic and metabolic changes in hepatic transplantation. (1989) (43)
Subclinical reactivation of hepatitis B virus in liver transplant recipients with past exposure (2003) (42)
Advances in primary sclerosing cholangitis. (1990) (42)
A controlled analysis of the transjugular intrahepatic portosystemic shunt in liver transplant recipients. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Liver Transplantation Database. (1997) (41)
Acute confusional state following liver transplantation for alcoholic liver disease (2002) (41)
A prospective study of pulmonary function and gas exchange following liver transplantation. (1992) (41)
Papillary bile duct dysplasia in primary sclerosing cholangitis. (1992) (41)
Role of endoscopic retrograde cholangiopancreatography after orthotopic liver transplantation. (1992) (41)
Survival after liver transplantation in diabetics. (1991) (40)
Evidence that the liver does not always protect the kidney from hyperacute rejection in combined liver-kidney transplantation across a positive lymphocyte crossmatch. (1990) (40)
The use of sirolimus should be restricted in liver transplantation. (2012) (40)
Epstein‐Barr virus and persistent graft dysfunction after liver transplantation (1991) (39)
Primary sclerosing cholangitis: a progressive disease? (1991) (39)
Neoral compared to Sandimmune is associated with a decrease in histologic severity of rejection in patients undergoing primary liver transplantation. (1997) (39)
Hepatitis C genotypes in liver transplant recipients: distribution and 1-year follow-up. (1995) (39)
A comparative study of patients undergoing liver transplantation for primary sclerosing cholangitis and primary biliary cirrhosis. (1991) (39)
Primary sclerosing cholangitis. (1984) (38)
Beyond 1 year after liver transplantation. (1989) (37)
Natural history and management of hepatitis C infection after liver transplantation. (2004) (37)
Evaluation of preoperative hematology-coagulation screening in liver transplantation. (1989) (37)
Systemic and Renal Effects of Nifedipine in Cyclosporine‐Associated Hypertension (1994) (37)
Prognostic significance and risk factors of untreated cytomegalovirus viremia in liver transplant recipients. (1996) (36)
Early cellular rejection after orthotopic liver transplantation correlates with low concentrations of FK506 in hepatic tissue (1995) (35)
Late hepatic allograft dysfunction (2001) (35)
Preliminary results: Outcome of liver transplantation for hepatitis B virus varies by hepatitis B virus genotype (2002) (35)
Hepatitis A antibodies in liver transplant recipients: Evidence for loss of immunity posttransplantation (2000) (35)
Hepatic allograft cyclosporine concentration is independent of the route of cyclosporine administration and correlates with the occurrence of early cellular rejection (1992) (35)
Ultrasound-assisted percutaneous liver biopsy performed by a physician assistant. (2002) (34)
METHODS TO ESTIMATE AND ANALYZE MEDICAL CARE RESOURCE USE (1999) (34)
Comparing nephrotoxicity of FK 506 and cyclosporine regimens after liver transplantation: preliminary results from US Multicenter trial. U.S. Multicenter Liver Study Group. (1995) (33)
Severe ductopenic rejection with features of vanishing bile duct syndrome: clinical, biochemical, and histologic evidence for spontaneous resolution. (1991) (33)
Enzyme inhibitory autoantibodies to pyruvate dehydrogenase complex in primary biliary cirrhosis: Applications of a semiautomated assay (1994) (33)
Central pontine myelinolysis with stupor alone after orthotopic liver transplantation. (1996) (33)
The nitric oxide donor sodium nitroprusside is protective in ischemia/reperfusion injury of the pancreas. (1998) (32)
Primary biliary cirrhosis has high wait‐list mortality among patients listed for liver transplantation (2017) (32)
Epidemiology and natural history of hepatitis C infections in liver transplant recipients. (1995) (31)
Mycophenolate Mofetil Use Is Associated with Decreased Risk of Late Acute Rejection in Adult Liver Transplant Recipients (2006) (30)
Human liver and conjugation of catecholamines. (1987) (30)
Excellent long-term survival following liver transplantation in primary sclerosing cholangitis patients (1998) (30)
Frequency, clinical presentation, and outcomes of drug‐induced liver injury after liver transplantation (2012) (30)
Application of the Mayo primary biliary cirrhosis survival model to Mayo liver transplant patients. (1989) (30)
Ultrasound-assisted percutaneous liver biopsy performed by a physician assistant (2002) (30)
Long-term outcome after liver transplantation. (1989) (29)
Predicting clinical and economic outcomes after liver transplantation using the mayo primary sclerosing cholangitis model and child‐pugh score (2000) (29)
Congestive gastropathy and other upper endoscopic findings in 81 consecutive patients undergoing orthotopic liver transplantation. (1990) (29)
Influence of human fulminant hepatic failure sera on endogenous retroviral expression in pig hepatocytes (2000) (28)
Combination immunosuppression with azathioprine reduces the incidence of ductopenic rejection and vanishing bile duct syndrome after liver transplantation. (1991) (28)
Etiology and natural history of primary sclerosing cholangitis. (1999) (28)
Precore and contiguous regions of hepatitis B virus in liver transplantation for end-stage hepatitis B. (1994) (28)
A positive lymphocyte cross-match and major histocompatibility complex mismatching do not predict early rejection of liver transplants in patients treated with cyclosporine. (1987) (27)
Risk Factors and Outcomes of De Novo Cancers (Excluding Nonmelanoma Skin Cancer) After Liver Transplantation for Primary Sclerosing Cholangitis (2017) (27)
Late recurrence and rapid evolution of severe hepatopulmonary syndrome after liver transplantation. (1999) (26)
Treatment of early cellular rejection following liver transplantation with intravenous methylprednisolone. The effect of dose on response. (1994) (26)
Is hepatic histology the true gold standard in diagnosing acute hepatic allograft rejection? (1996) (25)
Liver Transplantation and Hepatitis B (1997) (25)
Oral cyclosporine decreases severity of neurotoxicity in liver transplant recipients (1999) (25)
Simultaneous liver kidney transplantation (2019) (25)
Beyond 2000 (2001) (25)
Solid organ transplantation: Results and implications of acyclovir use in liver transplants (1993) (24)
Model for end‐stage liver disease (MELD) exception for bacterial cholangitis (2006) (24)
Advances in diagnosis, prevention, and management of hepatic allograft rejection. (1994) (24)
Factors Influencing Surveillance for Hepatocellular Carcinoma in Patients with Liver Cirrhosis (2016) (24)
Liver transplantation for jejunoileal bypass-associated cirrhosis: allograft histology in the setting of an intact bypassed limb. (1997) (24)
Addition of MMF to Dual Immunosuppression Does Not Increase the Risk of Malignant Short‐Term Death After Liver Transplantation (2005) (24)
The impact of cyclosporine dose and level on acute rejection and patient and graft survival in liver transplant recipients. (1998) (24)
Clinical and pathological features of graft-versus-host disease after liver transplantation: A case report and review of the literature (1993) (24)
Recent advances in the management of primary sclerosing cholangitis. (1987) (23)
Prognostic factors for successful conversion from cyclosporine to FK 506-based immunosuppressive therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group. (1993) (23)
Impact of Depressive Symptoms and Their Treatment on Completing Antiviral Treatment in Patients With Chronic Hepatitis C (2010) (23)
Anesthesia approach to hepatic transplantation. (1989) (23)
Persistent bile leak after liver transplantation: biloma drainage and endoscopic retrograde cholangiopancreatographic sphincterotomy. (1991) (23)
Blood bank support of a liver transplantation program. (1989) (23)
Serial determinations of the amino-terminal peptide of type III procollagen in severe chronic active hepatitis. (1987) (23)
IMMUNOHISTOLOGIC LABELING AS AN INDICATOR OF LIVER ALLOGRAFT REJECTION (1987) (23)
Impaired initial function in liver grafts from donors > 50 years of age. (1993) (23)
Primary nonfunction of the liver graft: when should we retransplant? (1991) (22)
Lymphocyte subsets in primary sclerosing cholangitis (1987) (22)
Impact of fibrosis progression on clinical outcome in patients treated for post‐ transplant hepatitis C recurrence (2015) (22)
Not All Cellular Rejections Are the Same: Differences in Early and Late Hepatic Allograft Rejection (2019) (21)
Hypertension after liver transplantation: a predictive role for pretreatment hemodynamics and effects of isradipine on the systemic and renal circulations. (2000) (21)
Liver transplantation for primary sclerosing cholangitis: impact of risk factors on outcome. (1996) (21)
Enhanced liver calpain protease activity is a risk factor for dysfunction of human liver allografts. (1997) (21)
Concentrations of 3,4‐Dihydroxyphenylalanine and Catecholamines and Metabolites in Brain in an Anhepatic Model of Hepatic Encephalopathy (1995) (21)
Cyclosporine A-induced side effects related to a low total serum cholesterol level: an indication for a free cyclosporine A assay? (1988) (20)
Orthotopic liver transplantation for preoperative early-stage hepatocellular carcinoma. (1994) (20)
Hepatitis C virus infection and lymphoproliferative disorders after liver transplantation (2000) (19)
Endotheliitis in hepatic allografts. (1989) (19)
Intragraft localization of activated nuclear factor κB in recurrent hepatitis C virus disease following liver transplantation (2000) (19)
113 A phase 2 dose-escalation study of albuferon combined with ribavirin in non-responders to prior interferon-based therapy for chronic hepatitis C infection (2006) (19)
Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. US Multicenter FK 506 Liver Study Group. (1993) (19)
Acquired (non‐Wilsonian) hepatocerebral degeneration: Complex management decisions (2003) (18)
The pathogenesis of hepatitis c virus (HCV) is strongly influenced by cytomegalovirus (CMV) (2002) (18)
Progression of primary biliary cirrhosis with ursodeoxycholic acid therapy. (1992) (18)
Curricular guidelines for training in transplant hepatology (2002) (18)
Acute fulminant hepatic failure. (1991) (17)
Hepatitis B virus replication patterns after orthotopic liver transplantation: de novo versus recurrent infection. (1993) (17)
Selective bowel decontamination to prevent gram-negative bacterial and fungal infection following orthotopic liver transplantation. (1987) (17)
Advanced liver failure predisposes to cyclosporine-induced central nervous system symptoms after liver transplantation. (1989) (16)
The autologous mixed lymphocyte reaction in primary biliary cirrhosis: Analysis of activation and blastogenesis of autoreactive T lymphocytes (1988) (15)
Is primary sclerosing cholangitis a progressive disease or not? (1988) (15)
MELD: the end of Child-Pugh classification? (2002) (14)
Liver transplantation for hepatitis B: the con aspect. (1995) (14)
Granulomatous destruction of bile ducts after liver transplantation: Primary biliary cirrhosis recurrence or hepatitis C virus infection? (1995) (14)
Erratum: Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: A prospective multivariate time-dependent analysis (Journal of Hepatology (1993) 18 (185-195)) (1993) (14)
Mayo end stage liver disease model (MELD) score predicts liver transpiant walting list mortality: Implications for liver allocation policy (2001) (14)
Hepatic allograft rejection is associated with increased levels of soluble intercellular adhesion molecule-1. (1995) (13)
Focal Dilatation of Intrahepatic Bile Ducts (Caroli's Disease), Cholangiocarcinoma, and Sclerosis of Extrahepatic Bile Ducts: A Case Report (1982) (13)
Other clinical studyEarly cellular rejection after orthotopic liver transplantation correlates with low concentrations of FK506 in hepatic tissue (1995) (13)
The incidence of gram-negative bacterial and fungal infections in liver transplant patients treated with selective decontamination (2005) (13)
Recurrence of ductopenic rejection in liver allografts after retransplantation for vanishing bile duct syndrome. (1991) (13)
Liver allograft iron accumulation in patients with and without pretransplantation hepatic hemosiderosis (2002) (12)
Diagnosis of cytomegalovirus hepatitis by histopathology and in situ hybridization in liver transplantation. (1991) (12)
Clinical evaluation of a new recombinant antigen-based cytomegalovirus immunoglobulin M immunoassay in liver transplant recipients. (2001) (12)
Applications of duplex ultrasonography in the liver transplant patient. (1990) (12)
Progression of primary biliary cirrhosis with ursodeoxycholic acid therapy. (1994) (12)
Factor XII Deficiency Acquired by Orthotopic Liver Transplantation: Case Report and Review of the Literature (2006) (12)
Results of treatment in hepatic allograft rejection depend on the immunohistologic pattern of the portal T lymphocyte infiltrate. (1988) (12)
Hepatitis G virus infection before and after liver transplantation. Liver Transplantation Database. (1997) (12)
Conversion from standard cyclosporine to low-dose cyclosporine and azathioprine therapy as treatment for cyclosporine-related complications in liver transplant patients. (1987) (12)
Immunohistologic pattern of the portal T-lymphocyte infiltration in hepatic allograft rejection. (1989) (12)
Original aricleInfluence of human fulminant hepatic failure sera on endogenous retroviral expression in pig hepatocytes (2000) (11)
Selective bowel decontamination for infection prophylaxis in liver transplantation patients. (1991) (11)
Hepatitis G virus infection in patients transplanted for cryptogenic cirrhosis: red flag or red herring? (1998) (11)
UW solution improves duration and quality of clinical liver preservation. (1990) (11)
D-penicillamine improves survival and retards histologic progression in primary biliary cirrhosis (1982) (10)
Management of ascites in patients with cirrhosis. What to do when diuretics fail. (1992) (10)
Prediction of liver transplant outcome using the MELD scale (2001) (10)
Soluble T lymphocyte markers in the diagnosis of cellular rejection and cytomegalovirus hepatitis in liver transplant recipients. (1994) (9)
Hepatitis C antibodies in patients with chronic hepatitis of unknown etiology after orthotopic liver transplantation. (1991) (9)
Liver and Kidney Recipient Selection of HCV-Viremic Donors - Meeting Consensus Report from the 2019 Controversies in Transplantation. (2020) (9)
Immunomodulating therapy in liver transplantation: principles and practice. (2012) (9)
The role of portosystemic shunts for variceal bleeding in the liver transplantation era. (1994) (9)
Fulminant hepatitis B virus: recurrence after liver transplantation in two patients also infected with hepatitis delta virus. (1997) (9)
Early cellular rejection treated with high-dose intravenous corticosteroid therapy is associated with a decrease in the incidence of steroid-resistant rejection and graft failure from rejection. (1993) (8)
Etiology and incidence of unconjugated hyperbilirubinemia after orthotopic liver transplantation. (1994) (8)
Do cold agglutinins have any impact on the outcome of liver transplantation? (1996) (8)
Acute Liver Failure Prognostic Scores: Is Good Enough Good Enough? (2016) (8)
Current therapies and clinical controversies in the management of primary sclerosing cholangitis (2000) (8)
Charcoal hemoperfusion in the treatment of medically refractory pruritus in cholestatic liver disease (2017) (8)
Should we change the priority for liver allocation for patients with the highest MELD score? (2012) (7)
Is primary sclerosing cholangitis a bad disease? (1987) (7)
Does propranolol precipitate hepatic encephalopathy? (1986) (7)
Pharmacokinetics of D-penicillamine in normals and primary biliary cirrhosis (PBC) (1979) (7)
PREVALENCE , IMPACT , AND ETIOLOGY OF RENAL INSUFFICIENCY IN LIVER TRANSPLANTATION Scope of the Problem and Impact on Outcomes (2009) (7)
The model for end-stage liver disease (MELD) score predicts survival in patients with spontaneous bacterial peritontis, and with ascites (2001) (6)
Subspecialty clinics : Pulmonary and critical care medicine : Hepatopulmonary syndrom with progressive hypoxemia as an indication for liver transplantation : Case reports and literature review (1997) (6)
Pharmacokinetics of cyclosporine in patients with primary biliary cirrhosis. (1988) (6)
The clinical significance of simultaneous infection with hepatitis G virus in patients with chronic hepatitis C (1999) (6)
Predictors of primary nonfunction: is donor liver fat content important? (1993) (6)
Evolving trends in liver transplantation: listing and liver donor allocation. (2014) (6)
Blood product transfusion therapy after liver transplantation: comparison of the thromboelastogram and conventional coagulation studies. (1993) (6)
The clinical significance of simultaneous infection with hepatitis G virus in patients with chronic hepatitis C. (1999) (6)
Antibody response to cytomegalovirus (CMV) polypeptides in liver transplant recipients with CMV hepatitis. (1992) (6)
Long-term comparison of tacrolimus versus cyclosporine in liver transplantation. The US FK Study Group. (1998) (6)
A comparison of azathioprine and cyclosporine in liver transplantation: a study of two personal series. (1987) (6)
456 Safety, pharmacokinetics and pharmacodynamic results of higher doses of albuferon in a phase single and double dose-escalation study in treatment experienced subjects with chronic hepatitis C (2004) (5)
Increasing peripheral T lymphocyte counts predict rejection in human orthotopic liver allografts (1988) (5)
Fulminant hepatitis B virus: Recurrence after liver transplantation in two patients also infected with hepatitis delta virus (1997) (5)
Immunohistochemical evidence of disease recurrence after liver transplantation for primary biliary cirrhosis (1996) (5)
Immunohistologic labeling of infiltrating T lymphocytes in hepatic allografts: a rejection indicator. (1987) (5)
Twelve years of liver transplantation at the Mayo Clinic. (1997) (5)
Reverse transcriptase-polymerase chain reaction fails to detect peripheral-blood hepatitis C RNA in formalin-fixed liver tissue. (1998) (4)
Effect of minimal listing criteria on waiting list registration for liver transplantation: a process-outcome analysis. (2003) (4)
Cytomegalovirus infection after liver transplantation: Incidence, timing, and predictors of disease severity (1991) (4)
435 Does the model for end-stage liver disease (MELD) predict post liver transplant graft survival? (2003) (4)
Association of α 1 Antitrypsin Phenotype and Development of Advanced Liver Disease and Pulmonary Complications Before and After Liver Transplantation. (2020) (4)
Kupffer cell expression of CD40L (CD154) in human chronic liver allograft rejection. (1999) (4)
Hepatocellular carcinoma in patients infected with different hepatitis C genotypes (1995) (4)
Lack of evidence for hepatitis B virus (HBV) infection in fulminant non-A, non-B hepatitis (1994) (4)
The MELD/PELD liver allocation policy is associated with a reduction in waiting list mortality while maintaining excellent posttransplant patient and graft survival (2003) (4)
Model for end-stage liver disease (MELD) predicts survival in patients with variceal bleeding (2003) (3)
Selective activation of suppressor T lymphocytes by cyclosporine in the autologous mixed lymphocyte reaction (1986) (3)
Moving toward evidence‐based liver allocation in patients with primary sclerosing cholangitis (2013) (3)
Prolonged anuria complicating primary sclerosing cholangitis: successful outcome following orthotopic liver transplantation. (1998) (3)
Granulocyte accumulation in the transplanted liver does not correlate with clinical and histologic evidence of dysfunction. (1996) (3)
Antemortem diagnosis and short-term survival of a patient with Wilson's disease presenting as fulminant hepatic failure (1984) (3)
Familial occurrence of liver disease and inflammatory bowel disease in primary sclerosing cholangitis (1987) (3)
EFFICACY OF MYCOPHENOLATE MOFETIL (MMF) IN LIVER TRANSPLANT RECIPIENTS: RESULTS OF A RANDOMIZED DOUBLE BLIND COMPARATIVE STUDY WITH AN ANALYSIS OF THE IMPACT OF HEPATITIS C.: Abstract# 27 (2000) (3)
INSULIN RESISTANCE, SERUM ADIPOKINES AND THE RISK OF FIBROSIS PROGRESSION IN PATIENTS TRANSPLANTED FOR HEPATITIS C: A PROSPECTIVE COHORT STUDY: 184 (2008) (3)
Is continued enthusiasm for ursodeoxycholic acid therapy for the treatment of primary biliary cirrhosis warranted? (1992) (3)
Primary Sclerosing Cholangitis and Celiac Disease (2020) (2)
Long-term management of liver transplant recipients (1993) (2)
S1801 A Multi-Centered Prospective Analysis of Long-Term Causes of Mortality Post Liver Transplantation: Results of the Niddk Database (2008) (2)
Unique hepatic gene expression in NASH-candidates for a genetic basis of disease (2001) (2)
Risk factors following for cytomegalovirus and severe bacterial infections liver transplantation: a prospective multivariate time-dependent analysis (1993) (2)
An open-label study of the safety and tolerability of converting stable liver transplant recipients to neoral. (1998) (2)
Is there disease progression in patients who are hepatitis C virus antibody–positive and hepatitis C virus RNA–seronegative? (2008) (2)
Superior Vena Cava Reconstruction Using An Iliocaval Allograft (1996) (2)
The spectrum of nonalcoholic fatty liver disease with normal liver enzymes (2003) (2)
Human leukocyte antigen DR markers as predictors of progression to liver transplantation in patients with chronic hepatitis C (2000) (2)
Advances in therapy for primary sclerosing cholangitis : Primary sclerosing cholangitis : recent developments (1992) (2)
Somatic muscle catabolism is accelerated after liver transplantation. (1993) (2)
Effects of cyclosporine on lymphocyte blastogenesis: Analysis of dose-response relationships and interindividual variability in healthy adults (1986) (2)
H14 - Effect of diuretics on blood pressure and cyclosporine nephrotoxicity after liver transplantation (TX) (1995) (2)
Heavy Alcohol Use Among Deceased Donors Does Not Impact Recipient Outcomes After Liver Transplantation (2018) (2)
131 Pulmonary vascular complications of liver disease: survival analysis of 140 patients evaluated at mayo clinic (2003) (2)
Primary Sclerosing Cholangitis and Other Cholangiopathies (2009) (1)
Exploring the Spectrum of Pathology and Treatment in Portopulmonary Hypertension: Four Experts Address the Toughest Questions (2004) (1)
Effect of cyclosporine dosing on creatinine levels in hepatic transplant recipients. (1994) (1)
PREDICTING OUTCOMES OF LIVER TRANSPLANTATION IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS (PSC) USING THE MAYO PSC MODEL AND THE CHILD-PUGH SCORE (1999) (1)
Competition and selection among different HCV strains (2001) (1)
183 RECURRENCE OF PRIMARY SCLEROSING CHOLANGITIS AFTER LIVER TRANSPLANTATION (2013) (1)
Rate, Risk Factors, and Outcomes of Cancer After Liver Transplantation for Primary Sclerosing Cholangitis: 2176 (2015) (1)
Progression of primary biliary cirrhosis on ursodeoxycholic acid. (1994) (1)
Cerebral Manifestations of Whipple's Disease: Dr. Wiesner replies (1988) (1)
Prophylaxis and Treatment of Cytomegalovirus Infection after Solid Organ Transplantation (2012) (1)
90th Annual Convention Poster Presentations and Abstracts (1991) (1)
Su1000 Patients With Primary Biliary Cirrhosis Have the Highest Wait-List Mortality (2015) (1)
Apply sound scientific methodology to the evaluation of new medical treatments (2011) (1)
842 Contemporary Predictors of Simultaneous Liver Kidney Transplant (SLK) and Post-Transplant Patient and Liver Graft Survival (2012) (1)
Chapter 20 – Primary Sclerosing Cholangitis (2006) (1)
Liver Transplantation and Blood Usage (1991) (1)
The Role of Cell-Based Bioartificial Liver Therapy in the Treatment of Fulminant Hepatic Failure (2002) (1)
430 Results of liver transplantation for hepatocellular cancer (HCC) under the MELD/PELD system for liver allocation (2003) (1)
Immunosuppression: The Global Picture (2011) (1)
Systemic arterial hypertension in the immediate postoperative period of liver transplantation: Role of endothelin? (1990) (1)
From the editorsThe changing of the guard: A new editorial team (2000) (1)
Getting ready for the second half (2002) (1)
WARM ISCHEMIA TIME IS AN IMPORTANT FACTOR FOR THE DEVELOPMENT OF NON-ANASTOMOTIC BILIARY STRICTURES. (1999) (0)
Benefit of living donor liver transplantation: Who and when? (2011) (0)
HIGHER PRETRANSPLANT HCV RNA LEVELS ASSOCIATED WITH POOR PATIENT AND GRAFT SURVIVAL (1998) (0)
127Recurrence of primary biliary cirrhosis after liver transplantation: An update on incidence (2000) (0)
Su1302 Predictors of Combined Liver and Kidney Transplantation and Post-Transplant Liver Graft, Kidney Graft, and Patient Survival: Comparison to Patients Receiving Listed for Kidney but Receiving Liver Alone (2013) (0)
Information of APPLE 2017 (2017) (0)
Primary sclerosing cholangitis: Advances in diagnosis, etiopathogenesis and treatment (1999) (0)
Human leukocyte antigen DR markers as predictors of progression to liver transplantation in patients with chronic hepatitis C. (2000) (0)
Predictors of Combined Liver and Kidney Transplantation and Post-Transplant Liver Graft, Kidney Graft, and Patient Survival: Comparison to Patients Listed for Kidney but Receiving Liver Alone. (2013) (0)
Low tacrolimus levels during the first week after liver transplantation are associated with an increased incidence of early acute rejection. (2001) (0)
DO DIURETICS IMPAIR RENAL FUNCTION AFTER TRANSPLANTATION?: Abstract# 791 Poster Board #‐Session: P48‐III (2000) (0)
THE POTENTIAL ROLE OF CLASS II ANTIGENS IN RECURRENCE OF PSC FOLLOWING LIVER TRANSPLANTATION. (1999) (0)
TISSUE HCV RNA LEVELS FOLLOWING LIVER TRANSPLANTATION FOR HEPATITIS C ‐ TIME COURSE AND IMPACT OF CYLCLOSPORINE VS. TACROLIMUS.: Abstract# 221 Poster Board #‐Session: P68‐I (2000) (0)
Mayo Clinic office visit. Organ donation. An interview with Russell Wiesner, M.D. (2006) (0)
P-305: The spectrum of large and small vessel changes in a model of developing human hypertension (HTN) (2003) (0)
Approaching our final year (2004) (0)
Su1004 Impact of Decompensation on Wait-List Mortality Among Patients With Listing MELD Score Below 15 (2015) (0)
CONCOMITANT ACTIVATION OF THE TRANSCRIPTION FACTOR NF-κB & NF-κB-RESPONSIVE INFLAMMATORY GENES IN HUMAN LIVER ALLOGRAFTS DURING CHRONIC DUCTOPENIC REJECTION (1999) (0)
Immunology of liver transplantation (1994) (0)
The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: The results of a pilot study (1995) (0)
Medical Aspects of Liver Transplantation (2002) (0)
107 INSULIN RESISTANCE, SERUM ADIPOKINES AND THE RISK OF FIBROSIS PROGRESSION IN PATIENTS TRANSPLANTED FOR HEPATITIS C: A PROSPECTIVE COHORT STUDY (2008) (0)
Prevalence and clinical significance of HFE gene mutations in patients undergoing evaluation for liver transplantation (2003) (0)
Safety and efficacy of thymoglobulin for steroid resistant acute cellular rejection following live rtransplantation (2007) (0)
Outcomes In the Pre-Rituximab and Post-Rituximab Eras In Post-Transplantation Lymphoproliferative Disorders (PTLD) In Adult Solid Organ Transplant Recipients (2010) (0)
Posttransplant lymphoproliferative disease following orthotopic liver transplantation (1995) (0)
Progression of Primary Biliary Ursodeoxycholic Acid Therapy (1992) (0)
Evolving Frequency with Graft and Patient Survival of Liver Transplantation Based on Etiology of Liver Disease Presidential Poster: 465 (2012) (0)
LIVER ALLOGRAFT NF‐KB ACTIVATION CORRELATES WITH SEVERITY OF HISTOLOGICAL DISEASE AND FIBROSIS IN HEPATITIS C VIRUS RECURRENCE.: Abstract# 599 (2000) (0)
The changing of the guard: A new editorial team (2000) (0)
L1: Cancer after liver transplantation (TX): Excess risk associated with calcium channel blocker administration? (1997) (0)
Incidence, Severity, and Outcome of Recurrent Hepatitis C is Similar in Patients Immunosuppressed with Neoral and Sandimmune (1998) (0)
Impact factor 2002 (2002) (0)
Anti-Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease Management in Liver Transplant Recipients: 1223 (2010) (0)
Is the prevalence of the HFE C282Y gene mutation and alpha 1 antitrypsin Z allele increased in patients with end-stage liver disease related to hepatitis C and other etiologies? (2003) (0)
Chapter 15 – Primary sclerosing cholangitis (2004) (0)
Reply: (2005) (0)
CARDIOVASCULAR RISK FACTORS AFTER LIVER TRANSPLANTATION (LT): COMPARISON OF MICROEMULSION CYCLOSPORINE (NEORAL), CONVENTIONAL CYCLOSPORINE (CSA), AND TACROLIMUS. (1999) (0)
ADAPTATION OF THE MAYO PRIMARY BILIARY CIRRHOSIS MODEL FOR MINIMUM LISTING CRITERIA FOR LIVER TRANSPLANT CANDIDATES (1998) (0)
[Complications and risk factors of ileo-anal anastomosis with reservoir for ulcero-hemorrhagic rectocolitis associated with primary sclerosing cholangitis]. (1993) (0)
CLINICAL AND ECONOMIC IMPLICATIONS OF USING ANTI-HBc-POSITIVE DONORS FOR LIVER TRANSPLANTATION (1998) (0)
Erratum: SRTR report on the state of transplantation:. Liver and intestine transplantation. American Journal of Transplantation (2003) 3 (78-90)) (2003) (0)
169Activation of the transcription factor NF-κB & induction of NF-κB-responsive inflammatory genes in human liver allografts during chronic ductopenic rejection (2000) (0)
vidence-Based Incorporation of Serum Sodium Concentration nto MELD (2006) (0)
Reply (2001) (0)
The pharmacokinetics of D-penicillamine in health and primary biliary cirrhosis (PBC) (1980) (0)
Rate, Risk Factors, and Outcomes of Recurrence of Primary Sclerosing Cholangitis After Liver Transplantation: 2168 (2015) (0)
LOWER QUALITY OF LIFE IN LIVER TRANSPLANT RECIPIENTS WITH HEPATITIS C.: Abstract# 398 Poster Board #‐Session: P38‐II (2000) (0)
Good news for our journal Liver Transplantation (2000) (0)
INCREASED MORTALITY FOLLOWING ACUTE CELLULAR REJECTION IN HCV-INFECTED LIVER TRANSPLANT RECIPIENTS (1999) (0)
Clinical epidemiology and assessment of disease severity among patients recently referred for evaluation at a major liver transplantation center (2000) (0)
REMOTE CONTROL: OUTCOMES UTILIZING TELEMEDICINE FOR OFF‐SITE PRE‐TRANSPLANT EVALUATION AND POST‐TRANSPLANT LONG‐TERM CARE.: Abstract# 989 (2000) (0)
Tu1013 De novo Non-Skin Malignancy Risk After Liver Transplantation for Primary Sclerosing Cholangitis (2013) (0)
ACTIVATION OF NF-κB IN HEPATITIS C VIRUS INFECTED LIVER ALLOGRAFTS (1999) (0)
197NF-κB activation in liver allografts correlates with severity of histological disease & fibrosis in recurrent hepatitis C virus disease (2000) (0)
Hepatic histology predicts outcome of OKT3 rescue therapy in liver transplantation (1990) (0)
Incidence, Diagnosis, Prevention, and Management of Acute Kidney Injury in Patients with Cirrhosis (2009) (0)
Recurrence of Primary Biliary Cirrhosis Following Liver Transplantation (2016) (0)
Sclerosing cholangitis. (1997) (0)
CURRENT APPROACH TO THE UTILIZATION OF LIVER DONORS POSITIVE FOR EITHER ANTI-HBC OR ANTI-HCV IN THE UNITED STATES. (1999) (0)
OUTCOME OF LIVER TRANSPLANTATION USING PEDIATRIC DONORLIVERS FOR ADULT RECIPIENTS. (1999) (0)
EARLY IDENTIFICATION OF RECIPIENTS WITH MORE SEVERE HISTOLOGICAL RECURRENCE OF HCV FOLLOWING LIVER TRANSPLANTATION.: Abstract# 593 (2000) (0)
History of Heavy Drinking Among Deceased Donors does not Affect Recipient Outcomes After Liver Transplantation (2017) (0)
P0031 : Frequency and outcomes of simultaneous liver kidney transplantation in NASH (2015) (0)
Thrombotic complications in liver transplant recipients for Budd-Chiari syndrome (2000) (0)
224 Safety and potential efficacy of etanercept in patients with alcoholic hepatitis: analysis of a recently completed pilot study (2003) (0)
The APPLE Association President's Message (2017) (0)
Prognostic factors in severe autoimmune chrcnic active hepatitis (ACAH): Role of orthotopic liver transplantation(OLT) (1991) (0)
B24 - Nocturnal hypertension after organ transplantation (TX) is mediated by systemic vasoconstriction and leads to pressure natriuresis (1995) (0)
M021: Delayed recovery of circadian blood pressure (BP) rhythm after cardiac transplant (TX) compared to liver TX at one year (1998) (0)
In a rapidly changing world, can we truly predict the impact of liver graft quality 15 years from now? (2015) (0)
ASSOCIATION OF HEPATITIS C WITH SUBCLINICAL REACTIVATION OF HEPATITIS B VIRAL DNA DETECTED BY POLYMERASE CHAIN REACTION (PCR) IN ALLOGRAFTS OF RECIPIENTS WITH APPARENT IMMUNITY TO HEPATITIS B (1999) (0)
THE EFFECT OF HLA-DR MATCH ON THE INCIDENCE OF NON-ANASTOMOTIC BILIARY STRICTURES AFTER LIVER TRANSPLANTATION. (1999) (0)
Asymptomatic PSC—Do they really have progressive diseases? (1991) (0)
Recurrence of primary biliary cirrhosis after liver transplantation: An update on incidence (2000) (0)
Diagnosing and managing primary sclerosing cholangitis (1997) (0)
Lack of an association between the HFE C282Y mutation and the alpha 1 antitrypsin allele in patients with end-stage liver disease (2003) (0)
Su1012 Frequency and Outcomes of Simultaneous Liver Kidney Transplantation in NASH (2015) (0)
The long-term outcome of liver transplant recipients with de novo hepatitis B infection who received an anti-HBC graft (2002) (0)
Su1003 Post-Transplant Outcomes at MELD>40 Are Better for Patients Receiving Simultaneous Liver Kidney Compared to Liver Transplant Alone (2015) (0)
Immunology of liver transplantation: Edited by James Neuberger and David Adams. 301 pp. $129.50. Little, Brown and Company, Boston, Massachusetts, 1993. ISBN 0-340-55310-3 (1994) (0)
208 Increased donor age is associated with increased risk of recurrent primary billiary cirrhosis following liver transplantation (2003) (0)

This paper list is powered by the following services:

Russell H. Wiesner's Academic­Influence.com Rankings

Russell H. Wiesner's Degrees

Why Is Russell H. Wiesner Influential?

Russell H. Wiesner's Published Works

Published Works

Russell H. Wiesner's AcademicInfluence.com Rankings